Skip to content

Brain Imaging and Cognition in Adults living with Duchenne Muscular Dystrophy

Brain Imaging and Cognition in Adults living with Duchenne Muscular Dystrophy - Adult DMD Brain research

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON52255
Enrollment
40
Registered
2021-10-21
Start date
2022-06-27
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne Muscular Dystrophy / Duchenne

Interventions

None listed

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Group A: DMD patients, MRI and NPE Group B: controls, MRI and NPE Group C: DMD patients, NPE For group A/C: Able to provide written informed consent Age 18 years or older Genetically confirmed diagnosis for DMD Male For group B: Able to provide written informed consent Age: maximally one year apart from a DMD participant (expected to be between 18-30 years old) Male

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study in group A: - MRI contraindications - Inability to complete the NPE A potential subject who meets any of the following criteria will be excluded from participation in this study in group B: - A diagnosis for any neurological or neuropsychological disorder - MRI contraindications - Inability to complete the NPE A potential subject who meets any of the following criteria will be excluded from participation in this study in group C: - Inability to complete the NPE

Design outcomes

Primary

MeasureTime frame
Main study parameters/endpoints: Presence or absence or significant differences in brain volumes structural connectivity, cerebral perfusion and functional connectivity between patients and healthy controls with respect to age, after applying the appropriate statistics per measure. Neurocognitive parameters and behavioural functioning will be assessed to describe the cohorts.

Secondary

MeasureTime frame
-

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)